Aqueous two-phase system for mRNA purification in IVT reaction and recovery methods

The ATPS method using PEG and kosmotropic salts for mRNA purification addresses scalability and degradation issues by rapid aggregation and filtration, achieving efficient and scalable mRNA and saRNA purification with minimal degradation.

WO2026236359A1PCT designated stage Publication Date: 2026-11-12
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/US2026/026897
Authority / Receiving Office
WO · WO
Patent Type
Applications
Priority Date
2025-05-06
Filing Date
2026-05-06
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

Current mRNA purification methods, particularly for self-amplifying RNA (saRNA), face challenges with scalability, prolonged processing times, and high risk of degradation due to extended residence times, which compromise product quality and yield in large-scale manufacturing.

Method used

An aqueous two-phase system (ATPS) using polyethylene glycol (PEG) and kosmotropic salts like sodium citrate is employed to rapidly and selectively aggregate mRNA, followed by direct membrane filtration, eliminating the need for centrifugation and complex chromatography, thereby reducing processing time to under 3 minutes and preserving RNA integrity.

Benefits of technology

The ATPS method achieves high recovery and impurity removal of mRNA and saRNA with minimal degradation, ensuring efficient and scalable purification compatible with continuous manufacturing, while maintaining RNA integrity and structure.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure US2026026897_12112026_PF_FP_ABST
    Figure US2026026897_12112026_PF_FP_ABST
Patent Text Reader

Abstract

A method of purifying mRNA from an in vitro transcription reaction is disclosed. The method involves preparing a stock solution of polyethylene glycol (PEG) in water, and mixing this stock solution with a kosmotropic stock solution of in water. The two stock solutions are mixed to form a PEG:kosmotrope system having immiscible PEG-rich and kosmotrope-rich phases. An in vitro transcription (IVT) reaction mixture is mixed with the PEG:kosmotrope system to obtain an lVT:PEG:kosmotrope system, the lVT:PEG:kosmotrope system is emulsified to obtain an emulsion comprising aggregated mRNA, and the aggregated mRNA is separated by a separation method such as filtration.
Need to check novelty before this filing date? Find Prior Art

Description

Attorney Docket No.: 105141- 101AQUEOUS TWO-PHASE SYSTEM FOR mRNA PURIFICATION IN IVT REACTION AND RECOVERY METHODS CROSS-REFERENCE TO RELATED APPLICATION

[0001] This application claims priority to U.S. Provisional Patent Application No.63 / 800,845, filed May 6, 2025, the disclosures of which are hereby incorporated by reference in their entireties.BACKGROUND

[0002] Recent advances in mRNA technology have revolutionized vaccine development, with the creation of highly effective COVID-19 vaccines and promising candidates for infectious diseases and cancer immunotherapy. As mRNA’s use expands in vaccines and gene therapies, there is an escalating demand for scalable and efficient mRNA production systems. In vitro transcription (IVT) has emerged as the leading method for large-scale mRNA synthesis, offering a flexible and reliable approach to generating high-quality mRNA for therapeutic applications. The IVT reaction mixture contains the components, including a DNA template, ribonucleotides (ATP, UTP, CTP, and GTP), RNA polymerase, buffer components, and cofactors, for efficient transcription. After the reaction, DNase digestion is used to remove the DNA template, but the resulting mixture still contains contaminants like unincorporated nucleotides, enzymes, residual DNA, double-stranded RNA (dsRNA), and incomplete or aberrant mRNA transcripts.

[0003] With the rise of large-scale in vitro transcription (IVT) reactions, the scale-up introduces a challenge: increased residence time during downstream processing. Extended residence time often results in mRNA degradation, as mRNA is prone to auto-hydrolysis, with a half-life of 1-4 hours in solution depending on its sequence. This degradation can compromise product quality and place added strain on subsequent separation steps.

[0004] To meet the downstream processing demand of a large-scale in vitro transcription reaction on a reasonable time scale, techniques such as ultrafiltration (UF), diafiltration (DF), or tangential flow filtration (TFF) are employed to remove low-molecular-weight contaminants like unincorporated nucleotides and enzymes, while simultaneously concentrating the mRNA. A process has been demonstrated using a 300kDa mPES membrane that successfully separated150624386.1Attorney Docket No.: 105141- 101100% of the rNTPs from the target mRNA while retaining 82% of the mRNA. However, processing just 20mL of the IVT reaction mixture took 38 minutes. Another approach utilizing a single-pass tangential flow filtration (SPTFF) process was presented, which reduced residence time, processing 200mL of IVT reaction mixture in approximately 32.8 minutes, while recovering nearly 100% of the mRNA and removing -60% of the protein. Despite these advancements, industrial GMP production of mRNA often involves reaction scales of 300-900mL, where most TFF processes result in extended residence times, leading to substantial mRNA degradation. Therefore, there is a desire for more efficient processes that effectively reduce the contaminant load before further downstream chromatography steps, while minimizing processing time and mRNA degradation, ensuring high-quality product yield even at large production scales.

[0005] Self-amplifying RNA (saRNA) is an emerging RNA modality that includes the gene of interest, a replication element derived from an alphavirus genome, and a gene encoding an RNA-dependent RNA polymerase. Since saRNA encodes for additional transcriptional machinery than just the gene of interest, saRNA molecules are larger than conventional mRNA, typically around 9-10 kb in length. While research has shown promising results regarding saRNA’ s effectiveness, its purification remains largely uncharted territory.

[0006] Currently, no commercially available, scalable purification process has been disclosed for saRNA. Although little has been published on the specific challenges associated with its purification, insights from mRNA purification suggest that increasing RNA size correlates with greater susceptibility to degradation. Given its extended length and complex secondary structures, saRNA is likely even more fragile than standard mRNA. Additionally, the long-stranded nature of saRNA can lead to unintended interactions, potentially entrapping smaller molecules like proteins, further complicating the purification process. These challenges are expected to be magnified at scale, posing a significant hurdle to the large-scale manufacturing and deployment of saRNA-based therapeutics.. . .SUMMARY

[0007] Aqueous Two-Phase Separation (ATPS) leverages the immiscibility of two aqueous phases, typically formed by mixing polymers (e g., polyethylene glycol) and salts and250624386.1Attorney Docket No.: 105141- 101exploits differences in the partitioning behavior of biomolecules, such as proteins, nucleic acids, and cells, between the two phases, enabling selective extraction and purification. ATPS is particularly advantageous for its gentle handling of biomolecules and scalability, in addition to its ability of ATPS to handle complex biological mixtures without denaturing sensitive biomolecules. In the context of mRNA purification, these characteristics of ATPS can be useful, since excessive shear force may degrade mRNA, and maintaining secondary structures to the mRNA helps maintain its functionality..

[0008] In accordance with embodiments of the invention a method is provided of purifying mRNA from an in vitro transcription reaction. For some embodiments, the method includes preparing a stock solution of polyethylene glycol (PEG) in water; preparing a kosmotropic stock solution of a salt of a kosmotropic anion in water; adjusting the pH of the kosmotropic stock solution to between about 6.0 and about 7.4, for some embodiments to about 6.9; and mixing the stock solution of PEG with the kosmotropic stock solution to form a PEG:kosmotrope system having immiscible PEG-rich and kosmotrope-rich phases; performing in vitro transcription (IVT) to obtain an IVT reaction mixture; mixing the IVT reaction mixture with the PEG:kosmotrope system to obtain an IVT:PEG:kosmotrope system; emulsifying the lVT:PEG:kosmotrope system to obtain an emulsion comprising aggregated mRNA; and separating the aggregated mRNA from the emulsion.

[0009] According to some embodiments, the w / w concentration of PEG in the PEG:kosmotrope system is between about 25% and about 35%, for some embodiments about 27.8%. According to some embodiments, the stock solution of PEG and the kosmotropic stock solution are mixed in a volume ratio of between about 2:3 and about 2:1, for some embodiments in a volume ratio of about 3:2.

[0010] For some embodiments, the mass of the IVT reaction mixture comprises between about 5% and 15%, for some embodiments about 10% of the total mass of the IVT:PEG:kosmotrope system. The kosmotropic anion can be selected from the group consisting of citrate, phosphate, and sulfate. For some embodiments, the salt of the kosmotropic anion is sodium citrate.

[0011] For some embodiments, prior to separating the aggregated mRNA from the emulsion, the emulsion is allowed to phase separate into three distinct macroscopic regions to350624386.1Attorney Docket No.: 105141- 101form a PEG-rich phase, a kosmotrope-rich phase, and an interfacial layer between the PEG-rich phase and the kosmotrope-rich phase, the interfacial layer comprising aggregated mRNA.

[0012] For some embodiments, the phase separation is accelerated by a process involving centrifugation. For some embodiments, emulsifying the IVT:PEG:kosmotrope system includes vortexing. For some embodiments, the aggregated mRNA is filtered to collect aggregated mRNA on a filter. For some such embodiments, the emulsion is filtered to collect aggregated mRNA on the filter prior to phase separation of the emulsion into distinct macroscopic regions. For some such embodiments, the IVT reaction mixture is mixed with the PEG:kosmotrope system to form the emulsion in a T mixer leading to a filter to collect the aggregated mRNA on a filter.

[0013] For some embodiments, the entire process of forming and filtering the emulsion is completed in less than five minutes. For some embodiments, the method includes dissolving the separated, aggregated mRNA in water to form an mRNA solution.

[0014] For some embodiments, the filter comprises silica glass. For other embodiments, the filter comprises a membrane filter. For some embodiments, dissolving the separated, aggregated mRNA in water involves adding water to the aggregated mRNA on the filter to form an mRNA solution.

[0015] For some embodiments, the method of purifying mRNA includes preparing a stock solution of polyethylene glycol (PEG) in water; preparing a stock solution of sodium citrate in water; adjusting the pH of the kosmotropic stock solution using citric acid to a pH between about 6.0 and about 7.4, for some embodiments to about 6.9; mixing the stock solution of PEG with the stock solution of sodium citrate to form a PEG:citrate system having immiscible PEG-rich and citrate-rich phases; performing in vitro transcription (IVT) to obtain an IVT reaction mixture; adding the IVT reaction mixture to the PEG:citrate system to obtain an IVT EG: citrate system; emulsifying the IVT EG: citrate system to obtain an emulsion comprising aggregated mRNA; separating the aggregated mRNA from the emulsion.

[0016] According to some embodiments, the w / w concentration of PEG in the PEG:kosmotrope system is between about 25% and about 35%, for some embodiments about 27.8%. For some embodiments the w / w concentration of sodium citrate in the PEG:kosmotrope system is between about 15% and about 25%, for some embodiments about 19.5%. For some embodiments, the stock solution of PEG and kosmotropic stock solution are mixed in a volume ratio of between about 2:3 and about 2:1, for some embodiments in a volume ratio of about 3:2.450624386.1Attorney Docket No.: 105141- 101

[0017] For some such embodiments, the mass of the IVT reaction mixture comprises between 5% and 15%, for some embodiments about 10%, of the total mass of the IVT EG: citrate system. For some such embodiments, emulsifying the IVT EEG: citrate system includes vortexing. For some such embodiments, the aggregated mRNA is filtered to collect aggregated mRNA on a filter.

[0018] Further disclosed is a purified sample of mRNA, prepared by embodiments of the methods described herein.BRIEF DESCRIPTION OF THE DRAWINGS

[0019] Fig. 1 is an overview of the ATPS process of the current disclosure.

[0020] Fig. 2A shows a tube containing the ATPS mixture immediately after mixing a PEG phase with a citrate phase with an in vitro transcription (IVT) reaction mixture.

[0021] Fig. 2B shows a tube containing the mixture of Fig. 2A after the mixture is allowed to phase separate into a PEG-rich phase, a citrate-rich phase, and a middle phase of aggregated RNA between the PEG-rich and the citrate-rich phases.

[0022] Fig. 3 shows a 1% denaturing formaldehyde agarose gel electrophoresis image of the mRNA in the in vitro transcription reaction mixture (labeled IVT) and samples collected from the middle phase by centrifugation and filtration with glass fiber spin filters followed by redissolution.

[0023] Fig. 4A provides results of protein removal and mRNA recovery following filtration of a fully separated aqueous two-phase system through a glass fiber spin filter.

[0024] Fig. 4B provides results of protein removal and mRNA recovery following filtration through a 0.22 pm GSWP membrane (mixed cellulose ester membrane).

[0025] Fig. 5 provides results of protein and rNTP removal efficiency following simplified direct filtration of ATPS-processed material, compared to conventional phase separation and filtration.

[0026] Fig. 6. compares protein removal, rNTP removal, and mRNA recovery for three different mRNA products following simplified direct filtration.

[0027] Fig. 7 shows representative chromatograms obtained using ion-pair reversed-phase high performance liquid chromatography (IP-RP HPLC).550624386.1Attorney Docket No.: 105141- 101DETAILED DESCRIPTION

[0028] Embodiments of the present disclosure provide a rapid and scalable method for purifying mRNA and self-amplifying RNA (saRNA) from in vitro transcription (IVT) reactions using a PEG:kosmotrope aqueous two-phase system (ATPS) combined with direct membrane filtration. By inducing spontaneous mRNA aggregation immediately after mixing, the process allows for direct capture by filtration without requiring complete phase separation or high shear operations. This approach overcomes limitations of current purification methods, such as long processing times, high risk of RNA degradation, and poor scalability, by reducing total purification time to under 3 minutes, preserving RNA integrity even for fragile and long constructs, and enabling simple and modular workflows compatible with large scale and continuous manufacturing. Embodiments of the present disclosure ensure high RNA recovery and impurity removal while eliminating reliance on centrifugation, ultrafiltration, or complex chromatography systems.

[0029] Several existing systems have been developed for the purification of mRNA following in vitro transcription, most notably ultrafiltration and diafiltration (UF / DF) using tangential flow filtration (TFF), enzymatic digestion combined with filtration, and lithium chloride precipitation. TFF -based methods can achieve reasonable contaminant removal and mRNA recovery but suffer from long processing times, often using over 30 minutes even for small reaction volumes, and expose mRNA to high shear forces that risk fragmentation. Lithium chloride precipitation is widely used for mRNA isolation but is slow, taking over an hour for complete precipitation and recovery, and uses harsh conditions that may damage RNA integrity. While ATPS have been explored for other biomolecules, including proteins and plasmid DNA, no previous system has disclosed a rapid, scalable ATPS method tailored for direct mRNA or saRNA purification.

[0030] Compared to these existing systems, embodiments of the present disclosure offer advantages, including faster processing times (under 3 minutes from emulsification to RNA capture), elimination of high shear stress, preservation of RNA integrity, simplified operation without centrifugation or alcohol-based precipitation, and compatibility with both standard mRNA and much larger, more fragile self-amplifying RNA (saRNA) constructs. Additionally,650624386.1Attorney Docket No.: 105141- 101this system uses biocompatible reagents such as PEG and kosmotropic salts, which are non-toxic and biodegradable, making the process more favorable for large scale manufacturing and regulatory acceptance. Such kosmotropic salts include but are not limited to citrate, phosphate and sulfate salts. For some embodiments the kosmotropic salt is sodium citrate.

[0031] As shown in Fig. 1, according to an embodiment, the purification process begins by constructing an ATPS composed of polyethylene glycol (PEG) and the kosmotropic salt sodium citrate. Stock solutions of PEG 600 (50% w / w) and sodium citrate (43.5% w / w) are prepared separately in nuclease-free water. The pH of the citrate solution is adjusted to about 6.9 using citric acid to ensure phase compatibility. These stock solutions are combined at a PEG-to-citrate volume ratio of 3:2, resulting in spontaneous formation of immiscible PEG-rich and citrate-rich phases. For other embodiments, the ATPS may comprise other kosmotropic salts, for example phosphate or sulfate salts. For some embodiments, the molecular weight of the PEG may be between about 300 and about 2000, or between about 400 and about 1000.

[0032] For the embodiment of Fig. 1, a crude in vitro transcription (IVT) reaction mixture, typically comprising approximately 10% w / w of the total ATPS mass, is added directly to the PEG-kosmotropic system. The solution is vortexed or agitated, e.g., 5 seconds, to ensure thorough mixing and emulsification. Upon mixing, a white, web-like mRNA-rich aggregate spontaneously forms at the interface between the two liquid phases, driven by the exclusion of RNA from the PEG phase and the ionic shielding effect of citrate ions.

[0033] For sample volumes below 1.1 mL, the entire phase-separated mixture (PEG-rich phase, kosmotropic salt phase, and interfacial aggregate) is loaded into a silica glass fiber spin filter (pore size ~1 pm) and centrifuged at 10,0007g to capture the aggregated RNA on the filter matrix. For larger volumes (>1.1 mL), a Swinnex filter holder containing a 0.22 pm hydrophilic membrane (e.g., Millipore GSWP) is used for dead-end filtration. The filtered RNA is retained on the membrane, while the PEG and kosmotropic salt phases pass through. In some embodiments, the emulsion is filtered immediately without a centrifugation-induced phase separation step.

[0034] For some such embodiments, the IVT reaction mixture is mixed with the PEG-citrate system in a T mixer configuration which feeds directly into a filter. In one such embodiment, the t-mixer has two inlet PEEK, 0.050" ID, 1 / 16" OD tubings, connected to a single High-Pressure Tee Assembly, PEEK, 0.050" ID, 1 / 16" OD Tubing, and one outlet with a PEEK,750624386.1Attorney Docket No.: 105141- 1010.050" ID, 1 / 16" OD tubing. For some embodiments, the injection of PEG and citrate is done with either a syringe pump or a peristaltic pump

[0035] For the embodiment of Fig. 1, captured RNA is reconstituted by adding nuclease-free water (equal in volume to the original IVT input or adjusted to desired volume), followed by 5 minutes of incubation with mild agitation. The solubilized RNA is collected and analyzed. RNA recovery is quantified using UV-Vis spectrophotometry (Nanodrop) or Qubit fluorescence assays, and purity is assessed by micro-BCA for protein contamination and ion-pair reversed-phase HPLC (IP-RP HPLC) for nucleotide impurities.

[0036] This method enables the selective, gentle, and rapid recovery of full-length mRNA and saRNA with reduced degradation and improved removal efficiency for proteins and residual rNTPs.

[0037] The process is compatible with batch and continuous formats and supports scale-up for industrial manufacturing.

[0038] Embodiments of the present disclosure provide rapid and efficient mRNA or saRNA purification. In some embodiments, composition of the aqueous two-phase system is adjusted, including the concentration and molecular weight of polyethylene glycol (PEG) and the type and concentration of the salt phase, provided that the system forms two immiscible aqueous phases and promotes RNA aggregation. In some embodiments, alternative salts to sodium citrate are used, such as phosphate or sulfate salts, or other salts of kosmotropic anions, so long as they induce similar RNA aggregation without compromising RNA integrity. In some embodiments, the method of inducing phase separation or emulsification, such as vortexing, stirring, or controlled mixing, is varied without impacting the fundamental aggregation and capture mechanism. In some embodiments, the pore size and material of the filtration membrane is adjusted, as long as the membrane effectively retains the RNA aggregate while allowing the liquid phases to pass through. In some embodiments, membranes having average pore sizes smaller or larger than about 0.22 microns are used, depending on the characteristics of the aggregate. Such characteristics may include size and shape distributions, and density of pores. For some such embodiments, theaverage pore size may be less than about 0.8 microns, about 0.7 microns, about 0.6 microns, about 0.4 microns, or about 0.3 microns. For some embodiments, the average pore size may be between 0.1 and 0.8 microns , or between about 0.1 and about 0.4 microns. For some embodiments, the average pore size is about 0.22 microns. The system is also 850624386.1Attorney Docket No.: 105141- 101adaptable to continuous or batch processing formats. In some embodiments, variations in temperature, flow rate during filtration, and volume ratios of IVT mixture to ATPS components are used.

[0039] Embodiments of the present disclosure include a PEG-kosmotrope aqueous two-phase system for purifying mRNA from the IVT reaction mixture, enabling rapid removal of protein and rNTPs from mRNA. The composition of this ATPS includes: the tie line length, pH, phase volume ratio and IVT load. Citrate salt provides the kosmotropic salt in some embodiments and has the advantage that citrate salt is biodegradable and non-toxic, with the added benefit of acting as a chelator to slow down mRNA degradation. The disclosed simple and rapid mRNA collection process from the phases formed after equilibration is demonstrated to be scalable and can enable continuous operation. A scalable purification process for saRNA using the ATPS is also demonstrated. For analytics, reverse-phase ion-pair chromatography was used to analyze results of the purification. This chromatographic process enables separation of components present in the in vitro transcription reaction, allowing us to assess the degree of purification and recovery.Examples

[0040] An ATPS was constructed by combining polyethylene glycol (PEG) 600 and sodium citrate stock solutions at a volumetric ratio of 3:2. The resultant mixture demonstrated clear and rapid phase separation within 30 minutes, yielding a PEG-rich upper phase and a citrate-rich lower. Centrifugation at 1000 x g significantly accelerated the phase separation process, reducing the time to approximately 1 minute.

[0041] Densitometry measurements facilitated the establishment of standard curves, enabling precise determination of equilibrium concentrations of PEG and citrate post-phase separation. The equilibrium concentrations were measured at 28.06% (w / w) PEG and 19.06% (w / w) citrate.

[0042] Upon the addition of 10% (w / w) crude in vitro transcription (IVT) reaction mixture, a cloudy emulsion formed in the form of a distinct white, web-like aggregate (Fig. 2A). This substance separated spontaneously from both PEG-rich and citrate-rich phases, forming a stable intermediate third phase between the original two phases (Fig 2B). Complete separation950624386.1Attorney Docket No.: 105141- 101into three distinct phases took over 30 minutes without intervention; however, centrifugation at 1000 * g for 1 minute expedited the process.

[0043] The intermediate phase exhibited a non-liquid consistency and was successfully isolated utilizing a spin fdter equipped with a 1 pm glass fiber filter. The collected substance was readily soluble in water, and subsequent analysis via UV spectroscopy (260 / 280 nm) and gel electrophoresis confirmed its identity as pure RNA. Gel electrophoresis results supporting these findings are shown in Fig. 3.

[0044] Without wishing to be bound by theory, the formation of a precipitated RNA phase is likely driven by the partitioning of mRNA out of the PEG-rich phase, in combination with the high concentration of the kosmotropic salt, in this embodiment sodium citrate, which reduces nucleic acid solubility. The elevated ionic strength of the citrate solution further shields the negative charges on RNA molecules, facilitating intermolecular interactions and promoting the aggregation of RNA into a distinct aggregate phase. This aggregate phase exhibits a density intermediate between the PEG-rich and citrate-rich phases, allowing it to equilibrate at the interface between these two phases.

[0045] Surprisingly, a simple filtration method can effectively collect the mRNA, as the aggregate formed was distinctly solid-like and sufficiently large to be easily observed with the naked eye. To validate this straightforward approach, we conducted a test using a 1 mb ATPS containing 10% w / w Flue mRNA (mRNA encoding for Firefly luciferase) in vitro transcription (IVT) reaction mixture, employing commercially available glass fiber spin filters. After the filtration step, the liquid PEG and citrate phases successfully passed through the filter, leaving the insoluble mRNA effectively captured by the glass fiber filter. Fig. 4A shows that effective protein removal and mRNA recovery can be achieved with the spin filter setup.

[0046] Typically, glass fiber filters used in nucleic acid recovery kits capture nucleic acids via ionic interactions and hydrogen bonding between nucleic acid phosphate groups and silica surfaces under conditions enhanced by chaotropic salts and alcohol. However, in the ATPS approach according to embodiments of the present disclosure, neither the PEG nor citrate phases contained any chaotropic salts or alcohol. Therefore, the mRNA capture mechanism relied on the size-exclusion properties of the glass fiber pores.

[0047] Re-dissolution of the captured mRNA was conveniently achieved by adding nuclease-free water directly onto the trapped mRNA retained on the filter. To ensure the mRNA 1050624386.1Attorney Docket No.: 105141- 101concentration remained constant, the volume of nuclease-free water was matched to the original IVT reaction volume that was introduced into the ATPS. Additionally, according to some embodiments, it is possible to adjust the amount of water used to redissolve the precipitated mRNA to either achieve dilution or concentration of mRNA before the subsequent downstream processes without additional steps. This method provides a practical advantage compared to conventional impurity removal techniques, such as tangential flow filtration (TFF), which typically result in dilution and therefore necessitate an additional concentration step prior to downstream purification.

[0048] Upon redissolution, the mRNA disaggregated due to the reduced sodium citrate concentration, which was no longer able to shield the negatively charged phosphate backbone. This condition promoted electrostatic repulsion between individual mRNA molecules. The disaggregated mRNA molecules were sufficiently small to readily pass through the glass fiber filter, allowing easy collection for subsequent downstream processing steps.

[0049] For larger-scale ATPS systems, spin filters were switched to 0.22 pm mixed cellulose ester (MCE) filters. Experimental results using IVT reactions containing Flue mRNA demonstrated 78.5% mRNA recovery with the 0.22 pm membrane, along with 96% of protein removal and approximately 99% of residual nucleotides (rNTPs) removal (Fig. 4B). Compared to glass fiber filters, the 0.22 pm membrane exhibited superior performance in capturing mRNA while still permitting efficient passage of liquid phases.

[0050] It was found that a 0.8 pm membrane failed to retain the insoluble mRNA (data no shown). Without wishing to be bound by theory, this outcome suggested that the 0.8 pm pore size was too large to capture mRNA particles under the pressure conditions of dead-end filtration. Despite glass fiber filters having pore sizes even larger than 0.8 pm, their increased thickness likely enabled the insoluble mRNA to penetrate beyond the surface and ultimately become trapped within the filter matrix. Lower mRNA recovery with the glass fiber filter suggested some mRNA fully traversed the filter and appeared in the flow through (Figure la and b). Conversely, the 0.22 pm membrane effectively captured the gel-like solid mRNA interface.

[0051] The third precipitant phase formed presented an opportunity to improve RNA collection methods. In traditional two-phase systems, target molecules are typically recovered from the liquid phases, utilizing full phase separation to maximize yield and purity. In contrast, for the present disclosure, as can be discerned from Fig. 2A, the formation of the mRNA1150624386.1Attorney Docket No.: 105141- 101aggregate was immediate upon mixing, creating a third phase between early coacervate droplets of PEG and citrate. These droplets later continue to separate into distinct PEG-rich and citrate-rich phases, causing the aggregated mRNA to consolidate at the interface. Surprisingly, it was found that the mRNA aggregates formed immediately after mixing are already large enough to be retained by a 0.22 pm membrane, and that full phase separation and centrifugation is not necessary prior to filtration.

[0052] It was found that the crude Flue mRNA-containing IVT reaction mixture was directly filtered through the membrane using a syringe pump at a flow rate of 10 mL / min, bypassing the centrifugation and complete phase separation step. Analysis of the recovered material revealed that this simplified approach surprisingly achieved comparable results to the traditional method: 78.57% to 84.76% of mRNA yield was recovered, measured by Qubit fluorometry and Nanodrop UV-Vis spectrophotometry, with approximately 97% of contaminating proteins removed, and 99% of residual rNTPs eliminated, as quantified by micro-BCA assays and IP-RP HPLC analysis. These results are summarized in Fig. 5, which compares protein removal, %rNTP removal, and % RNA recovery following simplified direct filtration of ATPS-processed material, compared to conventional phase separation and filtration.

[0053] The elimination of the centrifugation step reduced the total processing time from over 20 minutes to less than 3 minutes, dramatically accelerating the workflow. Furthermore, because the system relies on filtration, it becomes compatible with continuous or semi-continuous operation formats and easily scalable to industrial volumes. Centrifugation, especially at large scale, introduces operational complexity, equipment size limitations, and batch-to-batch variability. By replacing it with rapid membrane-based capture, this method simplifies the manufacturing process, lowers infrastructure costs, and enables faster, more reliable, and higher-throughput mRNA purification suitable for commercial production environments.

[0054] This ATPS was compatible with mRNA species of varying lengths and structures. IVT reaction mixtures containing Firefly luciferase (Flue) mRNA, mRNA encoding the SARS-CoV-2 spike protein (COVID mRNA), and an 11,000-nt self-amplifying RNA (saRNA) were evaluated. As summarized in Fig. 6, using the same ATPS composition and identical membrane dead-end filtration protocol, recoveries of 84.76% were achieved for Flue mRNA, 83.69% for COVID mRNA, and 87.60% for saRNA. Comparable recoveries across all mRNA types suggest1250624386.1Attorney Docket No.: 105141- 101that the mRNA, irrespective of length, formed aggregates mostly larger than 0.22 pm during the ATPS process, enabling effective capture by the membrane.

[0055] Without wishing to be bound by theory, the loss of mRNA may be attributed to a fraction of smaller aggregates passing through the membrane. It was observed that the recovery of saRNA was slightly higher than that of the shorter mRNA species, suggesting that the larger saRNA molecules formed more consistently oversized aggregates, potentially due to greater intermolecular entanglement and increased hydrodynamic radii, reducing the proportion of material below the membrane cutoff. We can show here that the ATPS-induced precipitation mechanism is robust across a wide range of mRNA lengths and can provide the efficient collection of longer RNA molecules. These results were reproducible across multiple independent preparations (n=3), confirming the reliability of the ATPS-based recovery method.

[0056] Similarly, as further summarized in Fig. 6, consistent protein removal efficiencies of 95.31%, 96.79%, and 98.07% were determined for Flue, COVID, and saRNA samples, respectively. As shown in Fig. 6, rNTP removal was also effective, with 98.88%, 97.39%, and 98.01% removal achieved for the three mRNA types.

[0057] As shown in Fig. 7, analysis of the recovered mRNA using IP-RP HPLC verified that the ATPS purification process preserved RNA structural integrity. The analysis revealed that the mRNA maintained the same peak shape and retention time after ATPS processing as observed in the original IVT stock solution, without the emergence of additional peak shoulders or degradation-related peaks. As expected, the ATPS method did not selectively separate fragmented mRNA from full-length transcripts; however, it also did not induce additional fragmentation during processing. These findings confirm that the rapid and gentle nature of the ATPS workflow, combined with the elimination of high-shear operations such as tangential flow filtration or prolonged centrifugation, effectively preserves RNA structural integrity throughout the purification process.

[0058] mRNA degradation during downstream processing is a concern, particularly because of the demonstration that the rate of mRNA degradation via hydrolysis is proportional to the transcripts’ lengths. Longer mRNA species, such as self-amplifying RNA (saRNA), are especially vulnerable due to their increased number of phosphodiester bonds and greater susceptibility to hydrolytic and enzymatic cleavage. Consequently, reducing process time is beneficial to preserve RNA integrity, especially for larger constructs. The ATPS developed in 1350624386.1Attorney Docket No.: 105141- 101this work offers an advantage by enabling RNA recovery in under 3 minutes at the laboratory scale, from emulsification to membrane collection. By eliminating the lengthy phase separation steps and extensive centrifugation, ATPS reduces the total residence time of mRNA in process environments where degradation risks are high. In addition to reducing process time, the ATPS workflow reduces mechanical stress and shear forces that can otherwise arise in tangential flow filtration (TFF) or column chromatography systems. It also limits the exposure window for potential RNase contamination by shortening open handling steps. These combined advantages help maintain RNA integrity and also suggest strong scalability potential; a similarly accelerated and gentler workflow at large production scales can substantially improve product yield, stability, and overall manufacturing efficiency for mRNA therapeutics.

[0059] As used herein, “about” as a modifier of a number implies a range of ±10%.

[0060] Although the invention has been described and illustrated with respect to exemplary embodiments thereof, it should be understood by those skilled in the art that the foregoing and various other changes, omissions and additions may be made therein and thereto, without parting from the spirit and scope of the present invention.Materials and Methods

[0061] Sodium citrate tribasic dihydrate and polyethylene glycol (PEG) 600 were obtained from Sigma-Aldrich (St. Louis, MO, USA). In vitro transcription (IVT) reaction mixtures and formulated mRNA were provided by Recipharm (Woburn, MA, USA). Protein concentrations were quantified using the BCA Protein Assay Kit (Thermo Fisher Scientific, Waltham, MA, USA), while mRNA concentrations were measured using the Qubit RNA HS Assay Kit (Thermo Fisher Scientific). Analytical separation was performed using a Shimadzu LC-2030 HPLC system (Shimadzu Scientific Instruments, Columbia, MD, USA) equipped with a PLRP-S column (PL1512-1503, Agilent Technologies, Santa Clara, CA, USA). Mobile phase buffers A and B were obtained from ADS Biotec (Omaha, NE, USA), and LC-MS grade acetonitrile (99.8%) was sourced from Thermo Scientific (Waltham, MA, USA). Small-volume filtration was carried out using spin filters from the High Pure RNA Isolation Kit (Roche Diagnostics, Indianapolis, TN, USA), and larger-volume filtration employed 0.22 pm mixed cellulose ester (MCE) membrane filters (MilliporeSigma, Burlington, MA, USA) housed in1450624386.1Attorney Docket No.: 105141- 10125 mm Swinnex Filter Holders (MilliporeSigma). Sample density measurements were performed using a Densitometer from Mettler Toledo (Columbus, OH, USA).Construction of Aqueous two-phase system

[0062] A 50% w / w master stock solution of polyethylene glycol (PEG) with a molecular weight of 600 was prepared by dissolving PEG in water. Similarly, a sodium citrate master stock solution was prepared by dissolving sodium citrate salt in water at a concentration of 43.5% w / w, which is close to the solubility limit of sodium citrate in water at room temperature. To facilitate the dissolution process and ensure sterility, both stock solutions were gently heated during preparation. The pH of the sodium citrate stock solution was carefully adjusted to 6.9 using an equimolar 1.87 M citric acid solution.

[0063] To construct the two-phase system, the PEG and sodium citrate stock solutions were mixed at a volume ratio of 1.5 (or 3 :2, PEG to citrate). The final weight percentages of PEG and sodium citrate in the mixed system were calculated based on the densities and initial weight percentages of the respective stock solutions.Measurement of the density and concentration of the phases after phase separation

[0064] The density of the PEG and citrate phases was measured using a densitometer, following the manufacturer’s instructions. To establish a standard curve, serially diluted solutions of PEG and citrate were prepared by diluting the master stock solutions with water. Density measurements were taken for each diluted solution and plotted against their corresponding concentrations.

[0065] Following the construction and phase separation of the PEG-citrate ATPS, 10 pL samples were collected from each phase (PEG-rich and citrate-rich) and analyzed using the densitometer. The concentrations of PEG and citrate in each phase were then determined by interpolating the density measurements against the previously established standard curve.in vitro transcription reaction mixture separation using ATPS

[0066] The in vitro transcription reaction mixture was prepared. 10%w / w in vitro transcription reaction mixture was applied to a constructed ATPS. After loading, the whole solution was emulsified by vortexing the test tube for 5 seconds. 0.11 g of IVT reaction mixture1550624386.1Attorney Docket No.: 105141- 101was loaded into a ImL ATPS for initial screening experiment, and 0.33 g of the reaction mixture was loaded into a 3 mL ATPS for later scale-up studies.RNA collection methods using a spin filter

[0067] For ATPS samples smaller than 1.1 mL, collection of insoluble mRNA or saRNA was conducted using silica glass fiber spin filters with a pore size of approximately 1 um (Roche). After centrifugation-assisted complete phase separation at 1,000 * g for 1 minute, the PEG-rich phase, citrate-rich phase, and the interfacial RNA layer were transferred into a spin filter. Samples were centrifuged again to pass the solutions through the spin filter membrane at 10000 x g for 1 minute, trapping the insoluble RNA. Residual liquid was removed by an additional brief centrifugation step at 10000 x g for 1 minute. RNA was then recovered by adding nuclease-free water equivalent to the original IVT reaction volume onto the spin filter membrane, followed by a 5-minute incubation with gentle agitation at 500 rpm. The reconstituted RNA was subsequently collected by centrifugation at 10000 x g for 1 minute.RNA collection methods using a membrane

[0068] For ATPS samples larger than 1.1 mL, filtration and collection of insoluble mRNA or saRNA were performed using a Swinnex housing unit fitted with a 0.22 pm GSWP membrane (Millipore). Initially, an ATPS was prepared by emulsifying 10% w / w of the in vitro transcription (IVT) reaction mixture. The insoluble RNA species accumulated at the interface between the PEG-rich upper phase and the citrate-rich lower phase. Phase separation was expedited by centrifugation at 1,000 * g for 1 minute. Following complete phase separation, the PEG-rich phase, citrate-rich phase, and interfacial layer were loaded into a 10 mL syringe, and filtered through the 0.22 pm membrane using a syringe pump (KD Scientific). To ensure thorough removal of residual liquid, 10 mL of air was subsequently passed through the membrane. Insoluble RNA species were then reconstituted by adding nuclease-free water equal to the volume of the original IVT reaction mixture onto the membrane, followed by incubation for 5 minutes with gentle agitation at 500 rpm. The dissolved RNA solution was then collected.

[0069] In subsequent experiments, the procedure was simplified by eliminating the waiting period for phase separation. The freshly prepared emulsion — comprising PEG-rich and citrate-rich phases with IVT mixture — was directly filtered at a controlled flow rate of 101650624386.1Attorney Docket No.: 105141- 101mL / min through the same Swinnex housing and membrane setup. RNA recovery was performed following the same protocol of reconstitution in nuclease-free water.mRNA or saRNA concentration assay

[0070] The concentration of mRNA or saRNA eluted in water was quantified using two complementary methods. First, UV spectroscopy was performed using a Nanodrop spectrophotometer for purified mRNA samples in water. If the mRNA was in a mixture with rNTPs, the RNA concentration was determined using the Qubit BR assay kit on a Qubit fluorometer, following the manufacturer’s instructions.Protein concentration assay

[0071] The protein concentration in the stock IVT reaction mixture was measured using a protein BCA assay kit. A standard curve was generated using prediluted Bovine Serum Albumin (BSA) standards with concentrations ranging from 125 pg / mL to 2000 pg / mL. To ensure the stock IVT reaction mixture for saRNA fell within the detection range, it was diluted by 100% prior to analysis.

[0072] For the collected mRNA or saRNA samples in water, protein concentration was determined using the micro-BCA assay kit. A separate standard curve was prepared using serially diluted BSA standards, with concentrations ranging from 2 pg / mL to 40 pg / mL, to accurately quantify the lower protein levels expected in these samples.IP-RP chromatography

[0073] Crude and purified mRNA samples were analyzed using ion pair reversed phase chromatography (IPRP) with an acetonitrile gradient. Chromatographic separation was performed on a polydivinylbenzene column (PLRP-S, 4000 A, 4.6 x 50 mm, 5 pm, Agilent) under denaturing conditions maintained at 75 °C. Both mobile phases were obtained from ADS Biotech Inc. Mobile phase A included 100 mM tri ethylammonium acetate (TEAA, pH 7.0), while mobile phase B contained 100 mM TEAA in 25% acetonitrile.

[0074] Analyses were conducted on a Shimadzu HPLC system (LC-2030) using the following gradient protocol: a constant flow rate of 0.5 mL / min was maintained throughout. The run began with 10% B for 5 column volumes, followed by sample injection. The gradient then proceeded from 10% to 25% B over 5 column volumes, 25% to 70% B over 10 column volumes,1750624386.1Attorney Docket No.: 105141- 10138% to 95% B over 1 column volume, held at 95% B for 5 column volumes, decreased to 2% B over 1 column volume, and held at 2% B for 5 column volumes.

[0075] Peak area analysis was performed using Shimadzu Post-run software. A 30-fold diluted in vitro transcription reaction mixture was used to determine the baseline amounts of proteins, ribonucleotides, and mRNA. Peak areas were normalized to the same mRNA input across samples to allow accurate comparison.

[0076] To quantify mRNA concentration in samples recovered in nuclease free water, a standard curve was established using known mRNA standards at concentrations of 1000, 800, 600, 400, and 200 ng / pL. Each standard was analyzed under the same IPRP conditions, and peak areas were plotted against known concentrations to generate a linear calibration curve. This standard curve was then used to determine the mRNA concentrations of experimental samples by interpolating their respective peak areas.1850624386.1

Claims

Attorney Docket No.: 105141- 101What is claimed is:

1. A method of purifying mRNA from an in vitro transcription reaction mixture, the method comprising:emulsifying the in vitro transcription (IVT) reaction mixture with polyethylene glycol (PEG) and a salt of a kosmotropic anion to obtain an emulsion comprising an emulsified IVT:PEG:kosmotrope system, the emulsified IVT:PEG:kosmotrope system comprising aggregated mRNA; andseparating the aggregated mRNA from the emulsified IVT:PEG:kosmotrope system.

2. The method of claim 1 of purifying mRNA from the IVT reaction mixture, wherein emulsifying the IVT reaction mixture comprises:obtaining a stock solution of PEG in water;obtaining a kosmotropic stock solution of a salt of the kosmotropic anion in water; adjusting the pH of the kosmotropic stock solution to between about 6.0 and about 7.4; mixing the stock solution of PEG in water with the kosmotropic stock solution to form a PEG:kosmotrope system having immiscible PEG-rich and kosmotrope-rich phases.emulsifying the IVT reaction mixture with the PEG:kosmotrope system to obtain the emulsified IVT:PEG:kosmotrope system.

3. The method of claim 1, wherein the mass of the IVT reaction mixture comprises between about 5% and about 15% of the total mass of the emulsified IVT: PEG:kosmotrope system.

4. The method of claim 1 wherein the kosmotropic anion is selected from the group consisting of citrate, phosphate, and sulfate.

5. The method of claim 1, wherein the salt of the kosmotropic anion is sodium citrate.

6. The method of claim 1, wherein prior to separating the aggregated mRNA from the emulsion, the emulsion is allowed to phase separate into three distinct macroscopic regions to form a PEG-rich phase, a kosmotrope-rich phase, and an interfacial layer between the PEG-rich phase and the1950624386.1Attorney Docket No.: 105141- 101kosmotrope-rich phase, the interfacial layer having an increased concentration of aggregated mRNA relative to the PEG-rich and the kosmotrope-rich phases.

7. The method of claim 6, wherein the phase separation is accelerated by a process involving centrifugation.

8. The method of claim 1, wherein emulsifying the in vitro transcription (IVT) reaction mixture with polyethylene glycol (PEG) and the salt of a kosmotropic anion includes vortexing.

9. The method of claim 1, wherein the aggregated mRNA is fdtered to collect aggregated mRNA on a filter.

10. The method of claim 9, wherein the emulsion is filtered to collect aggregated mRNA on the filter prior to phase separation of the emulsion into distinct macroscopic regions.

11. The method of claim 2, wherein the IVT reaction mixture is mixed with the PEG:kosmotrope system to form the emulsion in a T mixer leading to a filter to collect the aggregated mRNA on a filter.

12. The method of any one of claims 10 and 11, wherein the entire process of forming and filtering the emulsion is completed in less than five minutes.

13. The method of any one of claims 1 to 11, further comprising dissolving the separated, aggregated mRNA in water to form an mRNA solution.

14. The method of claim 9, wherein the filter comprises silica glass.

15. The method of claim 9, wherein the filter comprises a membrane filter.

16. The method of any one of claims 9, 10, 11, 12, 14, and 15, further comprising adding water to the aggregated mRNA on the filter to form an mRNA solution.2050624386.1Attorney Docket No.: 105141- 10117. The method of claim 2 wherein the kosmotropic stock solution comprises a stock solution of sodium citrate, and wherein the pH is adjusted with citric acid.

18. The method of claim 17, wherein the mass of the IVT reaction mixture comprises between about 5% and about 15% of the total mass of the emulsified IVT:PEG:kosmotrope system.

19. The method of claim 17, wherein emulsifying the in vitro transcription (IVT) reaction mixture with polyethylene glycol (PEG) and the salt of a kosmotropic anion includes vortexing.

20. The method of claim 17, wherein the aggregated mRNA is filtered to collect aggregated mRNA on a filter.

21. A purified sample of mRNA, prepared by any one of the methods of claims 1 to 11, 14, 15, and 17 to 20.2150624386.1